• Users Online: 66
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 4  |  Issue : 4  |  Page : 346-348

Saliva as an alternate specimen source for the diagnosis of coronavirus disease 2019 in symptomatic patients using cepheid xpert xpress SARS-CoV-2


1 Department of Pathology, Rashid Hospital, Dubai, United Arab Emirates
2 Department of Medical Affairs, Infectious Diseases Unit, Rashid Hospital, Dubai, United Arab Emirates
3 Department of Emergency, Rashid Hospital, Dubai, United Arab Emirates

Correspondence Address:
Dr. Maya Habous
Microbiology & Infection Control Unit, Pathology and Genetics Department, Rashid Hospital, Dubai
United Arab Emirates
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/bbrj.bbrj_170_20

Rights and Permissions

Background: Rapid and accurate SARS-CoV-2 diagnostic testing is essential for controlling the ongoing coronavirus disease 2019 (COVID-19) pandemic. The current gold standard for COVID-19 diagnosis is real-time reverse transcription-polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 from nasopharyngeal swab (NPS) specimens. The objective of this study is to assess saliva specimens for the diagnosis of COVID-19 using the GeneXpert® Xpress SARS-CoV-2 assay. Materials and Methods: In June 2020, we prospectively simultaneously collected saliva samples and a standard NPS from 60 patients meeting case definition of COVID-19 in the Emergency Department and from inpatients in Rashid Hospital at Dubai Health Authority during the outbreak of COVID-19. Real-time RT-PCR using the Cepheid Xpert Xpress SARS-CoV-2 was performed, and the results of the two specimens were compared. Results: A total of 60 paired NPS and saliva specimens were tested. An analysis of the agreement between the two specimens demonstrated a 97% observed agreement. 30/28 samples were positive in saliva when compared to the NPS, resulting in a positive percent agreement of 93%. 30/32 samples had a negative saliva and NPS. Two samples demonstrated detectable levels of SARS-CoV-2 nucleic acid in the saliva, but the NPS was negative, resulting in a negative percent agreement of 94%. Conclusion: Our data showed that saliva is an acceptable sensitive and specific alternative source for detecting SARS-CoV-2 nucleic acid and the use of saliva samples is safer and more convenient for the patient. NPS sampling inconsistency may be one of the potential issues for false-negative results.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed845    
    Printed24    
    Emailed0    
    PDF Downloaded87    
    Comments [Add]    

Recommend this journal